jueves, 6 de diciembre de 2012

New Federal Rule Provides Flexibility in Dispensing Buprenorphine for Opioid Addiction Treatment

New Federal Rule Provides Flexibility in Dispensing Buprenorphine for Opioid Addiction Treatment

United States Department of Health and Human Services, Substance Abuse and Mental Health Services Administration - A Life in the Community for Everyone: Behavioral Health is Essential to Health, Prevention Works, Treatment is Effective, People Recover

Rule Provides Flexibility in Dispensing Buprenorphine for Opioid Addiction Treatment
Today, SAMHSA issued a Federal rule to allow patients being treated through an Opioid Treatment Program (OTP) to receive take-home supplies of buprenorphine from an OTP in a more flexible manner. Buprenorphine is a medication used in opioid addiction treatment. The regulation takes effect on January 7, 2013.
Under the rule change, OTPs will be permitted to dispense buprenorphine to eligible patients without having to adhere to previous length of time in treatment requirements. Currently, OTPs require a person to be in treatment a certain amount of time before being given a multiple days' supply of medicine to take home.
The change in the rule will not affect requirements for dispensing methadone—the other opioid agonist treatment medication used by OTPs. SAMHSA based the change in the restrictions for dispensing buprenorphine on several factors. These include differences in the abuse potential between methadone and buprenorphine, as well as the actual abuse and mortality rates (buprenorphine is lower in each instance).

No hay comentarios:

Publicar un comentario